TrialLeukemia & lymphoma2017

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.

Abhishek Maiti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.